These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21576431)

  • 1. Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.
    Drusano GL; Lodise TP; Melnick D; Liu W; Oliver A; Mena A; VanScoy B; Louie A
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3406-12. PubMed ID: 21576431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
    Louie A; Liu W; Fikes S; Brown D; Drusano GL
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.
    Lodise TP; Sorgel F; Melnick D; Mason B; Kinzig M; Drusano GL
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1606-10. PubMed ID: 21300830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.
    Oshima K; Nakamura S; Iwanaga N; Takemoto K; Miyazaki T; Yanagihara K; Miyazaki Y; Mukae H; Kohno S; Izumikawa K
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
    Louie A; Fregeau C; Liu W; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3325-30. PubMed ID: 19364849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.
    Louie A; Liu W; VanGuilder M; Neely MN; Schumitzky A; Jelliffe R; Fikes S; Kurhanewicz S; Robbins N; Brown D; Baluya D; Drusano GL
    J Infect Dis; 2015 Apr; 211(8):1326-33. PubMed ID: 25362196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
    Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.
    Bilal H; Bergen PJ; Tait JR; Wallis SC; Peleg AY; Roberts JA; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid.
    Allegranzi B; Cazzadori A; Di Perri G; Bonora S; Berti M; Franchino L; Biglino A; Cipriani A; Concia E
    J Antimicrob Chemother; 2000 Aug; 46(2):319-22. PubMed ID: 10933662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
    Rodvold KA; Nicolau DP; Lodise TP; Khashab M; Noel GJ; Kahn JB; Gotfried M; Murray SA; Nicholson S; Laohavaleeson S; Tessier PR; Drusano GL
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3294-301. PubMed ID: 19451287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.
    Motos A; Kuti JL; Li Bassi G; Torres A; Nicolau DP
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.
    Benítez-Cano A; Luque S; Sorlí L; Carazo J; Ramos I; Campillo N; Curull V; Sánchez-Font A; Vilaplana C; Horcajada JP; Adalia R; Bermejo S; Samsó E; Hope W; Grau S
    Crit Care; 2020 Feb; 24(1):55. PubMed ID: 32066497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.
    Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Rogers KE; McGregor MJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.
    Tam VH; Schilling AN; Neshat S; Poole K; Melnick DA; Coyle EA
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4920-7. PubMed ID: 16304153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.
    Harigaya Y; Bulitta JB; Forrest A; Sakoulas G; Lesse AJ; Mylotte JM; Tsuji BT
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3894-901. PubMed ID: 19596879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model.
    Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
    Int J Antimicrob Agents; 2020 Feb; 55(2):105838. PubMed ID: 31705960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.